Kesimpta® is the official global commercial brand name, and Quanxinda is its Chinese brand name developed by Novartis. It is a fully human anti-CD20 monoclonal antibody for subcutaneous self-administration via pre-filled autoinjector. It selectively binds CD20 on mature B lymphocytes to deplete peripheral B cells, suppressing autoimmune inflammatory responses in multiple sclerosis.
Main Indications
Treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive multiple sclerosis.
Clinical Research
Global multicenter phase III ASCLEPIOS I & II pivotal trials fully validated its significant reduction in annualized relapse rate and brain MRI lesion activity versus teriflunomide;
Head-to-head comparative registration trials confirmed sustained B-cell depletion and lower infusion-related adverse events with subcutaneous self-injection administration;
Long-term open-label extension cohorts demonstrated durable disease control and consistent safety profile under monthly maintenance dosing;
Dose-finding research verified balanced efficacy and local injection-site tolerability of the 20 mg monthly subcutaneous regimen;
Chinese domestic registration trials confirmed stable lesion suppression and manageable adverse reactions for domestic relapsing multiple sclerosis patients.
Common Side Effects
Common mild adverse reactions: Injection-related reactions, upper respiratory tract infections, headache, fever and fatigue;
Laboratory abnormalities: Transient peripheral B-cell depletion, mild neutropenia and hypogammaglobulinemia;
Severe but uncommon risks: Severe systemic hypersensitivity reactions, serious bacterial/viral infections, progressive multifocal leukoencephalopathy and cardiac adverse events.
Approval Status in China
Original drug Kesimpta® (Chinese brand: Quanxinda) was officially approved for marketing in China in 2021, with the specification of 20 mg (0.4 mL) per pre-filled autoinjector, 1 autoinjector per box. It is a prescription disease-modifying therapy for multiple sclerosis included in China’s Category B medical insurance catalogue.
Buy Kesimpta (Ofatumumab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
